Remove 2026 Remove Immunization Remove Insurance
article thumbnail

The MEK effect on cancer — a slow and steady approach to drug resistance

PharmaVoice

You just want to slash it, rip it out or attack it like an enemy target,” said Benjamin Zeskind, co-founder, CEO and president of Immuneering Corporation. To overcome that hurdle, Immuneering is testing an approach that slows cancer down rather than rushing to destroy it.

article thumbnail

Navigating uncertainty: the future of vaccine oversight amid CDC firings

Pharmaceutical Technology

In a controversial move on 9 June 2025, US Secretary of Health and Human Services Robert F Kennedy Jr dismissed all 17 members of the Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP) that advises the federal government on vaccine safety.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Turning Reconciliation into a Revenue Growth Engine

Drug Topics

For instance, the MFP is expected to affect approximately 10 drugs in 2026, with the list expanding annually, potentially creating a $22,000 monthly financial impact for average retail pharmacies.

article thumbnail

GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients

Pharmaceutical Technology

A decision by the FDA is expected in H1 2026. A single dose of the vaccine in adults aged 18-49 at increased risk of RSV-LRTD elicited robust immune responses that were non-inferior to those observed in adults aged 60 and above. FDA approvals do not automatically mean shots enter national immunisation schedules.

article thumbnail

Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Pharmacy Times

1 For these reasons, the authors conducted this study to evaluate the clinical success and patient outcomes following the mandatory conversion from Humira to a biosimilar because of insurance-related restrictions.

article thumbnail

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat primary immunodeficiency (PI) in individuals aged two years and above. Credit: HenadziPechan/Shutterstock. Don’t let policy changes catch you off guard.

FDA 52
article thumbnail

EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL

Pharmaceutical Technology

A low incidence of immune effector cell-associated neurotoxicity syndrome was reported during the step-up dosing phase and the target dose phase. However, Blincyto’s loss of exclusivity in Europe (2025) and the US (2026) is expected to significantly reduce its future sales. billion for Blincyto. Sign up for our daily news round-up!